Target
Programmed death ligand 1 (PD-L1)
2 abstracts
Abstract
Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.Org: University of Louisville, James Graham Brown Cancer Center,
Abstract
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, NCI, Nihon Medi-Physics, National Cancer Institute, Vilnius, Lithuania, Institute for Clinical and Translational Research, Baylor College of Medicine,